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Summary Successful imaging or treatment of neuroblastoma With '3'I-meta-iodobenzy1guanidine ('3'I-mIBG)
depends on the selectivity of active (type 1) uptake of mIBG in neuroblastoma cells relative to passive (type 2)
uptake present in most normal tissues. This study investigates the effects of moderately elevated temperature
(39-41'C) on the cellular uptake of '3'I-mIBG in two neuroblastoma cell lines [SK-N-BE(2c) and IMR-32]
and in a non-neuronal (ovarian carcinoma) cell line (A2780). In SK-N-BE(2c), a cell line with high active
uptake capacity. the specific (type 1) uptake was reduced by 75% (P<0.001) at 39"C. Both IMR-32 and
A2780 have a low capacity for accumulation of mIBG by active uptake. These cell lines demonstrated a
statistically significant increase in accumulation at 39C, mainly as a result of increased non-specific transport.
At 41°C uptake of "3'I-mIBG was reduced in all cell lines. Thus, the active component of mIBG uptake is
more vulnerable to increased temperature than the passive component. It seems probable that moderately
increased temperature will have an unfavourable effect on the therapeutic differential for targeted radiotherapy
of neuroblastoma using radiolabelled mIBG.
Suvival rates in neuroblastoma. the most common extra-
cranial solid paediatric malignancy, have been improving less
rapidly than in other childhood tumours (Stiller & Bunch.
1990). Neuroblastoma is often widespread at diagnosis: 75%
of older children present with advanced disease. The prog-
nosis of this group is especially disappointing, with less than
20% surviving 2 years.
At present. first-line chemotherapy induces remission in
approximately 40% of patients. but about half of these will
relapse. To improve the survival of this group, consolidation
treatment using high-dose chemotherapy and bone marrow
rescue, with or without total body irradiation (TBI), is used.
Neuroblastoma is a relatively radiosensitive tumour, but the
dose administered by external beam radiation during frac-
tionated TBI is limited by normal tissue toxicity to about
14.4 Gy. which is probably insufficient for eradication of
macroscopic disease (Steel & Wheldon. 1992).
An alternative means of selective delivery of therapeutic
radiation to neuroblastoma employs the radiopharmaceutical
'3I-meta-iodobenzylguanidine (mIBG). This compound, a
guanethidine and bretylium analogue (Wieland et al., 1980),
is preferentially accumulated by cells of sympathetic nerve
origin via the noradrenaline uptake mechanism. This
mechanism is a characteristic of catecholamine-synthesising
cells such as adrenergic nerves and chromaffin cells (Jacques
et al., 1987). This specific uptake process has been well
characterised in a number of neuroblastoma cell lines in
culture (Buck et al., 1985; Lashford et al., 1991; Mairs et al.,
1991). The use of mIBG for diagnostic imaging and targeted
radiotherapy of neuroblastoma and phaeochromocytoma
exploits this mechanism (Hoefnagel et al., 1987).
The critical requirement for any form of targeted
radiotherapy is preferential uptake of the targeting agent by
tumour cells relative to normal tissues. In this case, fulfilment
of this condition requires high active uptake (type 1) in
neuroblastoma cells relative to the passive (type 2) uptake
which occurs in normal as well as tumour cells. Clinically,
neuroblastomas differ markedly in their active uptake of
mlBG (Moyes et al., 1989), making them of variable
suitability for ''I-mIBG treatment. Little is yet known of the
factors which control active uptake and how it can be
modified.
The effectiveness of combining '3'I-mIBG with elevated
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temperature has not yet been evaluated. Heat treatment has
been considered as an adjuvant agent to external beam radia-
tion for several reasons. Tumoricidal hyperthermia can
damage relatively radioresistant. S-phase cells in a poorly
nourished. hypoxic environment (Westra & Dewey. 1971;
Gerweck et al.. 1974; Sapereto et al.. 1978). Hyperthermia
acts synergistically with radiation, mainly through the inhibi-
tion of repair of potentially lethal damage and sublethal
damage (Ben Hur et al.. 1974; Hahn. 1974; Gerweck et al..
1975; Suit & Gerweck, 1979). However this generally occurs
at temperatures greater than 41.5'C. higher than those which
can be contemplated safely for systemic therapy.
Unlike external beam radiation, targeted radiotherapy is
characterised by low dose rate irradiation which is delivered
over a relatively long period of time. Whether the DNA
damage induced is sufficient to sterilise tumour cells depends
on a number of factors, including cellular uptake and reten-
tion of the targeting agent. We have assessed the effect of
moderately elevated temperature on the accumulation of
mIBG by neuroblastoma cells.
Information gained from experiments involving tempera-
tures slightly greater than 37°C might be useful in predicting
the likely effect of increased temperature on active and pas-
sive uptake of mIBG in higher temperature situations in
which concomitant cell sterilisation and lysis is a compli-
cating factor. We have therefore measured the uptake of
"'I-mIBG by two neuroblastoma cell lines at three tempera-
tures - 37°C 39'C and 41'C - using an ovarian cancer cell
line as a non-neuronal control. To differentiate between
active (type 1) uptake and passive (type 2) accumulation,
experiments were performed in the presence or absence of a
tricyclic antidepressant, desmethylimipramine. This prevents
the reuptake of neurotransmitters by adrenergic neurones
and has previously been shown to inhibit type 1 active
uptake (Mairs et al., 1991).
Materials and methods
Cell culture
Two well-established neuroblastoma cell lines. SK-N-BE(2c)
(Biedler et al., 1978) and IMR-32 (Tumilowicz et al.. 1970),
were used. These lines were chosen as they represent extremes
of mIBG uptake ability. The ovarian cell line A2780. a
variant of the cell line NIH:OVCAR-3, was used as a non-
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neuronal control (Hamilton et al., 1983). These cell lines were
regularly srened to ensure absnce of mycoplasma con-
tamination and were grown at 37C, in 5% carbon di-
oxide.
SK-N-BE(2c) and A2780 were cultured in RPMI-1640
medium with 25 mM HEPES buffer and supplemented with
10% fetal calf serum, penicillin and streptomycin
(100 IU ml-1), 2 mM L-glUtamine, 2mM amphotericin and
2 mM non-essential amino acids. IMR-32 was grown in
Ham's FIO medium with glutamine and the supplements
listed above. In addition, A2780 required 0.1% (v/v) insulin
(Boehringer Mannheim). All media and suppklments were
purchased from Gibco (Paisley, UK) unless otherwise
stated.
When in exponential growth the cells were harvested: SK-
N-BE(2c) and A2780 required trypsinisation, but IMR-32
cells were readily dislodged from culture vessels by shaking.
The cells were then subcultured into 25cm2 plastic tissue
culture flasks at an initial density of 0.3 million cells per
flask. When these cell monolayers were approximately 70%
confluent, they were assayed for '3'I-mIBG uptake.
Reagents
'311-meta-iodobenzylguanidine (131I-mIBG) (specific activity
37-185mBqmg-') was obtained from Amersham Interna-
tional (product code IBS 6711). Desmethylimipramine hy-
drochloride (DMI) was purchased from Sigma (Poole,
Dorset, UK).
'31I-mIBG uptake
All chemicals and media were first heated to the desired
temperature. Cells were incubated with or without 1.5 IM
DMI for 30min. This duration of the preincubation and
concentration of DMI used was previously shown to demon-
strate maximal drug inhibition of type 1 active transport
(Mais et al., 1991). At the end of this period, the medium
was replaced by one containing 0.1 mM 13'I-mIBG with or
without DMI. The cells were then incubated for a maximum
of 2 h at 37C, 39-C or 41-C. Experiments were performed in
thermostatically controlled water baths for maximum
accuracy. All solutions and media were first equilibrated to
the desird temperature before use. The temperature of the
flasks was meticulously checked throughout the
experiments.
In order to measure '311-mIBG uptke, the uptake process
was first terminated by washing with ice-cold phosphate-
buffered saline. The radioactive lysate was then extracted
from the cells by two 0.5-ml aliquots of 10% (w/v) trich-
loroacetic acid and measured in a sodium iodide crystal
gamma counter (Canberra Packard, Berkshire, UK). Cells
were harvested and counted and a mean number of cells
caulated for each flask.
Cell survival experiments
Cell survival was ass by clonogenic assay. Cells were
plated into sterile 25 cm2 flasks at an initial concentration of
1,000 cells per flask. They were incubated for 2 h at 3rC,
39-C or 41-C and then at 37C in 5% carbon dioxide to
allow colony formation. After 8-11 days the colonies were
fixed with ethanol and stained with Giemsa solution. Col-
onies of 50 or more cells were counted. The surviving frac-
tion was calculated as the number of colony-forming cells in
a treated group, relative to the control, corrected for plated
cell number.
Statistical analysis
Each experiment was repeated at least three times and six
replicates taken for each uptake point in the assay of mIBG
uptake. The data (Figure 1) represent sx independent repeats
of at least three experiments. The points plotted are the
arithmetic means of the uptake of mIBG in picomoles per
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Fige 1 The effect of temperature on the uptake of '3'IiBG
in three different cell lnes with and without the addition of
desmethylimipramne. a, SKNBE (2c). b, IMR-32. c, A2780.
million cells. The bands represent two standard deviations
from this mean. The data were analysed using Student's
t-test.
Reskts
At 3rC, comparison of the incorporation of 13'I-mIBG, at a
concentration of 0.1 mM, into SK-N-BE(2c) cells in the
presence or absence of 1.5mM DMI (Figure la) indicated
that about 98% was due to active uptake 1. At higher
temperatures there was a dramatic, statistically significnt
reduction in type 1 intracellular drug accumulation
(P<0.001). The inhibitory effect of the 41C incubation on
type I uptake was slightly greater than that of 39C
(P<0.02).
DMI was added to the medium to obtain inhibition of
specific transport. Elevated temperature had no significant
effect on the non-specific uptake by SK-N-BE(2c) cells. It
appears that the temperature-mediated decrease in '3I-mIlBG
uptake by SKNBE(2c) was a result of thermal denaturation
of the mIBG transporter molecule.
IMR-32 cells demonstrated low-level acquisition of 131j-
mIBG: approximately 10% of SK-N-BE(2c) levels through-
out the 2 h time course. In this cell line we observed (Figure
lb) a 3-fold increase in drug accunulation at 39C compared
with that at 37C after 1.5h (P<0.001).
A2780 was used as a non-neuronal control (Figure lc). A
similar but less pronounced temperature effect was noted in
the '3'I-mIBG entry into these cells. The increase in
accumulation at 39C compared with that at either 3rC or
41C was nonetheless highly significant (P<0.001).
Clonogenic cell survival studies demonstrated no
temperature dependence of survival for all three cell lines in
the range of 39-41C.
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mIBG is a valuable agent which has potential for use, in
combination with other treatments, with curative intent. It is
used therapeutically for the targeted radiotherapy of neuro-
blastoma and phaeochromocytoma (Hoefnagel et al., 1987),
and encouraging but variable results have been seen. The
therapeutic potential is limited by variation in uptake: some
individual tumours show poor accumulation of mIBG
(Moyes et al., 1989).
The cell line SK-N-BE(2c) demonstrated active, specific
type 1 uptake of '31I-mIBG, which has been well charac-
tenised elsewhere (Lashford et al., 1991).
Neuroblastoma cells retain high intracellular levels of
mIBG by a dynamic equilibrium of diffusion and re-uptake
(Smets et al., 1990). If mIBG were given with hyperthermia,
heat denaturation of the monoamine receptor ATPase might
(if irreversible) diminish the tumour uptake of administered
mIBG or inhibit the re-uptake of egressed drug.
We found that the active accumulation ofmlBG by SK-N-
BE(2c) cells was markedly reduced by eklvated temperature.
One possible explanation is that the transport protein may
have been structurally altered at 39-C and 41-C. This is
plausible as it has been shown previously that some memb-
rane proteins can undergo a thermotropic transition starting
at 39-C (Verma et al., 1977). In addition, the ability of the
Ca-ATPase of sarcoplasmic reticulum to transport calcium
has been shown to be reduced at 40-45-C (Cheung et al.,
1987). Na+,K+-ATPases (Szmigielski & Janiak, 1978) as well
as other membrane transport systems (Kwock et al., 1978)
have been shown to be inhibited at temperatures greater than
43-C.
The effect of temperature alteration on the radiopharma-
ceutical uptake by the cell line IMR-32 was less clear. Since
these cells have poor uptake 1 capacity and the elevated
temperature-dependent enhnement of mIBG uptake was
observed both in the presence and absence ofthe monoamine
transport inhibitor DMI, the increased accumulation of
mIBG at 39-C seems to involve non-specific uptake
mechanisms. A similar effect of temperature elevation has
been noted for passive molcular transport (Strom et al.,
1973) in Ehrlic ascitic tumour cells. These exhibit an
exponential increase in passive diffusion of radiolabelled
uridine across the cell membrane with increasng tempera-
ture. Although the effects were marked at 44C the data also
support increased passive diffusion at 41C and below.
Mechanisms of mlBG uptake which do not involve the
noradrenaline receptor are not yet well elucidated but may
involve electrochemical gradients (Lampidis et al., 1989). It
has been shown that an abrupt reduction of membrane
potential associated with an increased alkcali cation
permeability occurs at temperatures greater than 38-C in
human erythrocytes (Mikkelson & Wallach, 1977). As mIBG
exists in cationic form at physiological pH, some ofthe entry
into cells incubated at temperatures greater than 3TC could
be due to eklctrophoretic migration mediated by altered elec-
trochemical gradients.
The observed incrae in uptake of radiopharmaceutical at
39 C by both IMR-32 and the non-neuronal control cell
suggests that a non-specific general effect on the cell mem-
brane may operate at this temperature. The membrane effects
of hyperthermia are extensively studied and have been re-
viwed elsewhere (McLaren & Pontiggia, 1990; Marcocc &
Mondovi, 1990). In general, these changes are mediated by a
change in conformation ofmembrane proteins rather than by
changes in lipid motion or order (Lepocc, 1982).
In the present experiments the uptake of '3'I-mlBG at 41-C
was poor in all cell lines, probably because of the denatura-
tion of critical membrane proteins.
We conclude, therefore, that hyperthermia should not be
combined with targeted '311-mIBG in tumours in which good
uptake of the radiopharmaceutical is anticipated as this may
lead to an increased accumulation in non-target tissues and
hence a lower therapeutic differential. Further studies are
warranted to determine whether or not the increased uptake
of mIBG seen at moderately increased temperature (39C) in
poorly uptaking cells can lead to an improved therapeutic
differential.
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